Healthcare company Organon (NYSE: OGN) announced on Monday that it has finalised its acquisition of Dermavant Sciences Ltd, a provider of therapeutic solutions in immuno-dermatology, expanding its dermatology offerings with VTAMA (tapinarof) cream, a novel, non-steroidal, nonbiologic topical treatment for adults with plaque psoriasis.

Approved by the FDA for mild, moderate, and severe plaque psoriasis, VTAMA is free from safety warnings on duration or body surface limitations. Additionally, the FDA is reviewing a supplemental application for VTAMA as a treatment for atopic dermatitis in adults and children aged two and up, with a decision expected in Q4 2024.

This acquisition aligns with Organon's commitment to women's health and broadens its product scope across multiple therapeutic areas. With its global presence and a strong commercial footprint, Organon continues to seek new partnerships and innovations in health, focusing on accessible treatments worldwide.

Dermavant's parent company, Roivant, will continue its work in immunology, autoimmune and respiratory disease treatments through its robust biopharmaceutical pipeline.